We investigated the impact of glucose control on target lesion restenosis after PCI in patients with type 2 diabetes. Methods: Ninety-three consecutive patients with type 2 diabetes accepted for PCI were randomised to intensified glucose control based on insulin (I-group; n=44) or to continue ongoing glucose-lowering treatment (C-group; n=49). The treatment target was a FBG of 5-7 mmol/L and HbA1c <6.5%. Information on target lesion restenosis after six months was available in 82 patients. Results: At baseline HbA1c and FBG did not differ between the I-and C-groups, respectively (HbA1c: 6.5 vs. 6.5%; p=1.0 and FBG: 7.0 vs. 7.3 mmol/L; p=0.3). After six months there was no significant change in HbA1c or FBG in either group (change in HbA1c: -0.2 vs.-0.1%; p=0.3 and in FBG: +0.2 vs. -0.3 mmol/L; p=0.3 in the I-and C-groups, respectively). Target lesion restenosis at six months did not differ, I vs. C = 41 and 44% (p=0.8). Independent predictors for restenosis were previous myocardial infarction (OR 8.0, 95% CI 2.5-25.7; p=<0.001) and FBG at baseline (OR for an increase by 1 mmol/L = 1.4, 95% CI 1.1-1.9; p=0.015). Conclusions: Restenosis was predicted by baseline FBG suggesting that it would be of interest to target glucose normalisation in future trials. Intensified insulin treatment did not influence the rate of restenosis indicating that the main focus should be on lowering glucose rather than the tool to normalise glucose.
Introduction
PCI is a frequently used technique for revascularisation of patients with stable as well as unstable coronary artery disease. The results of PCI are less favourable in patients with diabetes than in those without diabetes due to a higher restenosis rate in the former group than in their non-diabetic counterparts as summarised in the recent guidelines on diabetes and cardiovascular disease. 1 After PCI with bare metal stents at least 30% of the diabetic patients will develop restenosis compared with 20% or less in patients without diabetes. 2 The subsequent high demand for repeat revascularisation procedures exposes the diabetic patients to an increased risk for periprocedural complications. 3 The introduction of drug eluting stents has reduced the need for target lesion revascularisation but the restenosis rate still remains higher in diabetic compared with non-diabetic patients. 1, 4 Thus, there is a need for further attempts to decrease the risk of restenosis after PCI in the diabetic population.
Patients with diabetes have an enhanced propensity to atherosclerosis that involves a more aggressive dyslipidaemia with particularly atherogenic low-density lipoprotein, haemostatic perturbations and endothelial dysfunction. 5 These processes are further enhanced by hyperglycaemia. Even a modest elevation of fasting glucose is associated with increased mortality after PCI 6 and poor glycaemic control is associated with a more dismal outcome after a myocardial infarction. [7] [8] [9] In contrast improved metabolic control decreases microvascular complications. 10 The effect of hyperglycaemia and mode of glycaemic control on the rate of restenosis after PCI is, however, less well explored. As reviewed by Aronson et al. 5 it has been argued that hyperinsulinaemia, as present particularly in diabetic patients treated with insulin, may enhance the proliferative response after a PCI. In contrast to this assumption, observations from the first Diabetes mellitus Insulin-Glucose infusion in Acute Myocardial Infarction (DIGAMI) trial 11 and studies in patients in intensive care 12 has indicated that insulin-based glycaemic control may be important for the prevention of cardiovascular events.
The primary objective was to test the hypothesis that improved glucose control, achieved by adding or optimising insulin treatment, will reduce the rate of restenosis after PCI in patients with type 2 diabetes.
Methods
The Insulin Diabetes Angioplasty (IDA) study recruited consecutive patients with type 2 diabetes accepted for PCI as treatment for coronary artery disease. Following oral and written informed consent, patients were invited to participate regardless of ongoing glucose-lowering treatment. They were stratified regarding type of PCI, acute or elective, and subsequently randomised to an intensified insulin-based glucose control (I-group) or to continue ongoing glucose-lowering treatment (C-group). Exclusion criteria were: acute myocardial infarction within 48 hours before the intervention; inability to participate for physical or psychological reasons; residency outside the hospital catchment areas.
Elective patients
Attempts were made to optimise glycaemic control during the three weeks preceding the PCI in elective patients randomised to the I-group. The aim was to achieve an HbA1c level <6.5%, FBG 5-7 mmol/L and blood glucose before meals <10 mmol/L. Whole blood glucose was analysed with a photometric technique (Hemocue  AB, Ängelholm, Sweden) while HbA1c was analysed by high-performance liquid chromatography in a core laboratory (Department of Laboratory Medicine, Malmö University Hospital, Sweden) on capillary blood applied on filter paper with an upper normal limit of 5.3% (Boerhringer Mannheim Scandinavian AB, Bromma, Sweden). The results obtained from this method can be recalculated to the international standard (IFCC standard) as follows: Swedish HbA1c = 0.989 (IFCC-HbA1c) + 0.88%; (r 2 =0.996). 13 The patients in the I-group were seen by a specially trained nurse and physician at the diabetic clinic once weekly prior to the PCI and during the continuation of the study at least once monthly. They were instructed to monitor their glucose before each meal and in the evening at least three days a week. The protocol stated treatment with fast-acting meal insulin three times daily and long-acting insulin at bedtime. This treatment was initiated by bed-time insulin (human isophane, Insulatard ® , Novo Nordisk) with the dose adjusted to obtain FBG of 5-7 mmol/L. If blood glucose still exceeded 10 mmol/L insulin human or insulin lispro (Actrapid ® , Novo Nordisk or Humalog ® , Lilly) was added before meals.
Elective patients randomised to the C-group continued ongoing glucose-lowering treatment (i.e. insulin, oral agents or combinations). Any change in their diabetes medication was at the discretion of the attending physician.
Acute patients
Patients with unstable coronary artery disease, in whom revascularisation was deemed necessary within few days and that were randomised to the I-group, were immediately brought to the best possible glucose control by means of a glucose-insulin infusion aiming at a blood glucose level of 4-9 mmol/L. The infusion continued for at least 12 hours after the PCI. After termination of the infusion these patients followed the treatment outlined for elective patients. Acute patients allocated to the C-group continued ongoing glucose-lowering treatment according to the discretion of their attending physician.
PCI
Balloon angioplasty and coronary stenting were performed according to the standard at the time of the study. 14 A ≥50% luminal diameter reduction was defined as significant. A bare metal stent was applied if the vessel diameter was ≥3 mm, if the balloon dilatation was suboptimal or if it caused dissection, otherwise only balloon dilatation was recommended. After stent implantation the goal for the intervention was a residual stenosis <20% 15 of the reference diameter measured online with QCA in combination with thrombolysis in myocardial infarction 3 flow. 16 If the lesion length was >15 mm and/or the vessel diameter <3 mm, a residual stenosis of <50% at the dilated site measured online with QCA was accepted as successful in order to avoid multiple or long stents.
Follow-up
All patients were seen after two weeks and at one, three and six months after the PCI. Repeat coronary angiograms could either be performed on clinical grounds (symptoms indicating restenosis) or according to the protocol after six months. Patients with a negative coronary angiography before that time were reinvestigated at six months while an already verified restenosis was accepted without further angiography.
Definitions and angiographic analysis
All patients had previously known diabetes accepted as type 2 if the patient was >35 years of age at onset of disease and without any demand of insulin during at least two years thereafter. All procedural and follow-up angiograms were analysed offline with the cardiovascular measurement system (Medis, Leiden, The Netherlands) by two blinded interventionists. Matched angiographic views were obtained for each patient before and after the procedure and at six months follow-up. The inter-observer variability was 0.2 mm. Late loss was calculated from the MLD after the index intervention subtracted by the MLD at follow-up. Angiographic restenosis was defined as a ≥50% diameter stenosis at the treated site. If multiple lesions had been dilated late loss was expressed as the mean value of all target lesions.
Statistics
Continuous variables are expressed as median and lower and upper quartiles and the Wilcoxon random test was used for differences between groups. Categorical variables are expressed as numbers and percentages and analysed using the Fisher exact test. Logistic regression analysis was performed to identify univariate predictors of restenosis. Multiple logistic regression analysis was performed with restenosis at six months as a dependent variable and variables are presented in Table 1 as candidate predictors. Predictors with a p-value ≤0.2 (previous myocardial infarction, concomitant disease, known hyperlipidaemia, ticlopidine/clopidogrel at discharge, stroke/ TIA, diabetes complications, CABG and fBglucose at baseline) were entered into a best subset selection.
It was assumed that the restenosis rate would be between 30% and 40% 2 and that a reduction to 25% would be clinically meaningful. Then a calculated number of 170 patients in each group were required for a significance level of 5% and a power of 80%. A two-sided p-value of <0.05 was accepted as statistically significant. All statistical analyses were performed using SAS software version 9.1.3 (SAS Institute).
Ethical considerations
The IDA study was conducted according to good clinical practice and the Helsinki declaration. All patients participating received oral and written information and written informed consent was obtained prior to inclusion. The trial was approved by the Ethics Committee at the Karolinska Institutet.
Results
A total number of 102 patients were recruited and equally distributed with 51 each in the I-and C-groups, respectively. Of these, 28 were included as acute patients, 14 in the I-and 14 in the C-groups, respectively. The planned PCI was not performed in three patients and six withdrew their original consent to participation in the study. The final study group, in which restenosis could be assessed, consisted of 82 patients (I-group = 39; C-group = 43). A new coronary angiography was performed prior to six months in 14 patients because of their symptoms, which in nine resulted in a new PCI and in four coronary bypass surgery. One patient with a target lesion left anterior descending stenosis underwent bypass grafting of this vessel four months after the index PCI and was accepted as having a restenosis. Six patients did not undergo the angiogram due to unwillingness and five for medical reasons including cancer, salmonella and Addison's disease. Among the latter, two had symptoms of angina during the follow-up period. The remaining 67 patients had a coronary angiography performed after six As outlined in Table 2 there were no important differences in baseline characteristics and medical treatment between the two groups. The median age was 66 and 62 years in the I-and C-groups, respectively and the proportions of females:males were 26:74% and 24:76%, respectively. Descriptive variables from the index PCI are presented in Table 3 . The glucometabolic control was equivalent in the two groups at the time of randomisation without any significant difference in FBG (I-group 7.0 mmol/L vs. C-group 7.3 mmol/L) and HbA1c (6.5% in both groups) (Table 1) .
At the control six months after the PCI there was no significant change in blood glucose in either of the two groups. Fasting glucose increased by 0.2 mmol/L in the I-group and decreased by 0.3 mmol/L in the C-group (p=0.3). The proportion of target lesion restenosis was similar in both groups (I-group 41% vs. C-group 44%; p=0.8). Regardless of the randomised treatment, the proportion of renewed target vessel intervention was similar in the two study groups (Table 3 ). There was an average weight gain in the I-group of 0.5 kg compared with a weight loss of -0.8 kg in the C-group (p=0.3). No severe episodes of hypoglycaemia were reported in either of the two groups.
Since the two study groups did not differ as regards achieved glucometabolic control and restenosis rate, an analysis was performed to look for predictors of restenosis within the complete patient cohort. Characteristics in patients divided by restenosis are shown in Table 4 and univariate predictors for restenosis at six months in Table 5 . Actual diabetes treatment at six months, i.e. insulin or oral treatment irrespective of randomisation, did not influence the rate of restenosis.
Following adjustments in a multiple analysis the only significant predictors of restenosis were FBG at randomisation (OR for + 1 mmol/L = 1.44, 95% CI 1.07-1.92; p=0.015) and previous myocardial infarction (OR 8.00, 95% CI 2.49-25.67; p=<0.001).
Discussion
The main finding in the IDA trial was that FBG prior to PCI is an independent predictor of restenosis in patients with type 2 diabetes. Intensified administration of insulin did not further reduce the rate of restenosis.
It may be argued that restenosis following PCI is a minor problem in the presence of drug eluting stents. However, recent reports indicate that even with the use of such stents there is a high demand for repeated revascularisations. 4 Moreover Lee et al. 17 recently reported that diabetic patients with multivessel coronary artery disease treated with PCI and drug eluting stents had a significantly higher need for revascularisation during the first year than those treated with bypass surgery. Thus attempts to improve the outcome after PCI in patients with diabetes remain important.
The present finding of the predictive importance of hyperglycaemia is consistent with a report by de Luca Mean of values at randomisation, two weeks, one, three and six months et al. 18 defining hyperglycaemia as plasma glucose >7 mmol/L at the time of PCI. Similarly Lindsay et al. 19 found that a periprocedural plasma glucose >128 mg/dl (i.e. >7.1 mmol/L) was related to an increased rate of target lesion revascularisation even in the presence of HbA1c <7.0%. Poor metabolic control expressed as elevated HbA1c, defined as either >7.0% or >8.0% at the time of a PCI, has also been related to restenosis in patients with type 2 diabetes. 20, 21 HbA1c has been demonstrated as a predictor of restenosis even in patients without diabetes. 22 Previous investigations did not include information on the level of glycaemic control from the time of a PCI until restenosis and the present study adds information of potential importance by clarifying the temporal relationship between glycaemia and restenosis in a diabetic population. Indeed both groups in the IDA study were fairly well controlled with a median HbA1c level around 6.5% (equivalent to 7.5% according to the Diabetes Control and Complications Trial (DCCT) standard). It may be hypothesised that a high glucose level at the time immediately before and after the PCI is more important than the subsequent metabolic control. This assumption may have important implications when planning future trials for attempting to decrease the rate of restenosis following PCI in diabetic patients. As reviewed by Aronson et al. 5 there are several potential links between restenosis and hyperglycaemia. Although the exact mechanism is not fully understood, one may speculate that the immediate periprocedural environment influences the restenosis process and that an unfavourable milieu is initiated directly when balloon inflation causes endothelial injury and denudation. The endothelial cell layer is particularly vulnerable and its function compromised in diabetic patients. In the presence of hyperglycaemia, the endothelium-dependent production of nitrous oxide may be decreased and oxidative stress promoted causing an over-production of free oxygen radicals which activate protein kinase C. This may trigger the release of a large number of pro-inflammatory molecules thereby contributing to the induction of delayed healing of the vascular injury, further endothelial dysfunction, and cellular proliferation in the vessel wall enhancing the risk of restenosis. 23 At comparable levels of glycaemic control the rate of restenosis was not reduced in patients randomised for intensified insulin treatment compared with patients left with ongoing therapy (the C-group). This finding was also true when analysing the actual treatment with insulin, irrespective of randomisation. This indicates that insulin does not exert beneficial or detrimental effects per se compared with other glucose-lowering modalities. Similarly, observations made in the DIGAMI 2 trial indicated that for a similar glycaemic control insulin was not superior to other glucoselowering therapies in protection from cardiovascular events. 24 These observations support the concept that meticulous glucose control rather than insulin treatment is more important as reported by van den Berghe et al. 12 The implication of, and optimal timing for, a meticulous glycaemic control in the context of restenosis after PCI remains to be established underlining the need for further investigations. Although hoped for, the IDA trial did not
give a clear answer to the question of whether a normalisation of blood glucose would have decreased the rate of restenosis. It may be argued that the target for metabolic control in the IDA trial was too high, although it was in accordance with then existing guidelines. Present recommendations for a fasting plasma glucose <6.0 and a post-prandial level of <7.5 mmol/L in combination with a DCCT standardised HbA1c <6.5% is even more strict. 1 Although patients in the I-group had their glucose level supervised and adjusted in a specialised diabetes clinic, their glucose levels did not improve. This demonstrates the difficulties in managing glucose control even with an insulin-based regime in this type of patients. It highlights the need for improved treatment modalities. The present observations are not unique. Previous reports from intervention trials trying to improve glucose levels by intensified insulin experienced similar problems. 24, 25 
Study limitations
An increasing problem during the study period was a change in clinical practice with the introduction of drug eluting stents. Since such stents may have had a major impact on the main outcome parameter, restenosis, the study protocol, originally only prescribing the use of bare metal stents, was not amended to avoid an unsystematic use of drug eluting stents that may have severely biased the outcome. Unfortunately this, in combination with some loss of patients during the study period, resulted in a smaller than planned number of participating patients with a loss of statistical power, particularly with regard to the evaluation of the impact of insulin-based therapy. This comparison was, as already outlined, also hampered by a somewhat less intensive than planned glucose control. The rate of restenosis was high, above 40%. Considering the outcome of no difference in glucose control between patients in the I-and C-groups, respectively, it is unlikely that an increased number of patients would have changed the outcome regarding the impact of insulin.
Conclusion
The periprocedural FBG was significantly related to the rate of restenosis after adjusting for potential confounders in this group of patients with type 2 diabetes. Intensified insulin treatment did not reduce the rate of restenosis. These observations make it of interest to target glucose normalisation during the nearest time for PCI while the tool to achieve this seems less crucial. This study was supported by grants from the Swedish Heart Lung foundation and AFA insurance. The authors are grateful to Associate Professor John Öhrvik for statistical advice and Kerstin Höglund RN and Kerstin Wadenvik RN for taking care of the patients and obtaining blood samples. 
